source
- Migraine biotech Vedana Therapeutics raises $46 million Series A to advance preclinical pipelineVedana Therapeutics, a new biotech focused on migraine, has announced its emergence from stealth mode after securing a Series A financing round. The company raised $46 million from investors, whic…
- Neumora ends development of navacaprant after failed Phase 3 depression trials; EnGene cuts half its workforceNeumora Therapeutics announced it will discontinue its kappa opioid receptor antagonist navacaprant after the drug missed its primary endpoints in two Phase 3 studies for major depressive disorder.…